Navigation Links
Reportlinker Adds Prostate Cancer Drug Futures
Date:10/19/2010

NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Prostate Cancer Drug Futures

http://www.reportlinker.com/p0315764/Prostate-Cancer-Drug-Futures.html

AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Prostate Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.

24/7 web access

Quarterly updated pdf reports

Single cost-effective price

All updates including any new drugs added during your license period

Related news

Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

The prostate cancer (PC) market is on the verge of considerable change....

....with the imminent arrival of new targeted therapies that will prolong patient survival. PC is the second leading cause of new cancer cases in men worldwide and the sixth leading cause of cancer death in men. In the US, over two million men currently suffer with PC and it is estimated that there were 192,311 new cases and 29,698 deaths due to the disease in 2008. There have been dramatic improvements in PC survival over the last 25 years, mainly due to a combination of earlier diagnosis and improvements in treatments, although rates vary between countries

The PC market was estimated to be worth US$5.2 billion in 2008; it is one of the larger segments of the oncology market, alongside breast, non-small cell lung and colorectal cancers. The market is currently driven by the use of hormonal therapies, which are prescribed mainly for advanced hormone-dependent PC. However, the market dynamics will change considerably over the next six years as patents expire and generic competition intensifies. Research into new therapies is extremely active and new agents with novel modes of action are being evaluated.

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Prostate Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...

Track the drug's progress and stay abreast of developments

Understand the drug's novelty and mode of action

Evaluate the strength of the company developing/producing the drug

Review opportunities and challenges with Espicom's unique 5-point competitive assessment

Know the launch timeframe for new products or indications

Be aware of promising mid-stage development candidates

Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates

Review significant clinical trial results

STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…

Novelty/rationale for mechanism of action

Current status

Proof of concept/clinical data

Development risks

Company expertise

Competition within the market-place

Sales forecast (for key late-stage and launched products)

Competitor ratio analysis score

Clinical trial results

OVER 45 PROSTATE DRUGS INCLUDE:

Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved

Bicalutamide

Cabazitaxel

Degarelix

Docetaxel

Goserelin

Leuprorelin

Mitoxantrone

Paclitaxel

Sipuleucel-T

Filed

Dutasteride

Phase III

Abiraterone acetate

Aflibercept

Dasatinib

Ipilimumab

Radium-223

ZD4054

Phase II

AT-101

Bortezomib

Cixutumumab

E75 GM-CSF adjuvant vaccine

Enzastaurin

Figitumumab

Ixabepilone

OGX-011

OnyVax-P

PROSTVAC

Ramucirumab

Sagopilone

Vadimezan

CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

Table of ContentsOVERVIEW .... 1

PHASE I... 3

AE37 . 3

Mode of Action .. 3

Current Status ... 3

Proof of Concept/Clinical Data ... 3

Development Risks . 5

Company Expertise . 5

Competition within the Market-place 5

Competitor Ratio Analysis 5

ASP0265 . 6

Current Status ... 6

SAR109659 .... 7

Mode of Action .. 7

Current Status ... 7

Proof of Concept/Clinical Data ... 7

Development Risks . 8

Company Expertise . 8

Competition within the Market-place 8

Competitor Ratio Analysis 9

Clinical Trial Results .... 9

PHASE I/II .. 11

BORTEZOMIB ... 11

Mode of Action 11

Current Status .11

Proof of Concept/Clinical Data .12

Development Risks 13

Company Expertise 13

Competition within the Market-place ....13

Data Exclusivity .....14

Patent Expiry ...15

Generic Competition ....15

Competitor Ratio Analysis ....15

Forecast ...16

Clinical Trial Results ....17

PHASE II ..... 20

AT-101 .. 20

Mode of Action 20

Current Status .21

Proof of Concept ...21

Development Risks 21

Company Expertise 21

Competition within the Market-place ....22

Competitor Ratio Analysis ....22

Forecast ...22

CIXUTUMUMAB 23

Mode of Action 23

Current Status .23

Proof of Concept/Clinical Data .24

Development Risks 24

Company Expertise 24

Competition within the Market-place ....24

Competitor Ratio Analysis ....25

CUSTIRSEN SODIUM ... 26

Mode of Action 26

Current Status .26

Proof of Concept/Clinical Data .26

Development Risks 27

Company Expertise 27

Competition within the Market-place ....28

Competitor Ratio Analysis..28

DEGARELIX 29

Mode of Action 29

Current Status .29

Proof of Concept ...29

Development Risks 29

Company Expertise 30

Competition Within the Market-place ...30

Competitor Ratio Analysis ....30

Forecast ...31

DOVITINIB ... 32

Mode of Action 32

Current Status .32

Proof of Concept/Clinical Data .33

Development Risks 33

Company Expertise 33

E75 GM-CSF ADJUVANT VACCINE ..... 34

Mode of Action 34

Current Status .34

Proof of Concept/Clinical Data .34

Development Risks 35

Company Expertise 35

Competition Within the Market-place ...35

Competitor Ratio Analysis ....36

Forecast ...36

ENZASTAURIN.. 37

Mode of Action 37

Current Status .37

Proof of Concept/Clinical Data .37

Development Risks 38

Company Expertise 38

Competition within the Market-place ....38

Competitor Ratio Analysis ....39

Forecast ...39

Clinical Trial Results ..40

ERBULIN ..... 41

Clinical Trial Results ....41

FIGITUMUMAB .. 42

Mode of Action 42

Current Status .42

Proof of Concept ...42

Development Risks 43

Company Expertise 43

Competition Within the Market-place ...43

Competitor Ratio Analysis ....44

Clinical Trial Results ..45

IXABEPILONE ... 46

Mode of Action 46

Current Status .46

Proof of Concept/Clinical Data .47

Development Risks 47

Company Expertise 48

Competition within the Market-place ....48

Competitor Ratio Analysis ....48

Forecast ...49

Clinical Trial Results ....49

LY2181308 ... 52

Mode of Action 52

Current Status .52

Proof of Concept/Clinical Data .52

ONYVAX-P .. 53

Mode of Action 53

Current Status .53

Proof of Concept ...53

Development Risks 53

Company Expertise 53

Competition within the Market-place ....54

Competitor Ratio Analysis ....54

Forecast ...54

PROSTVAC . 55

Mode of Action 55

Current Status .55

Proof of Concept ...55

Development Risks 55

Company Expertise 56

Competition within the Market-place ....56

Competitor Ratio Analysis ....56

Forecast ...56

RAMUCIRUMAB 57

Mode of Action 57

Current Status .57

Proof of Concept/Clinical Data .57

Development Risks 57

Company Expertise 58

Competition within the Market-place ....58

Competitor Ratio Analysis ....58

Forecast ...59

SAGOPILONE ... 60

Mode of Action 60

Current Status .60

Proof of Concept/Clinical Data .60

Company Expertise 60

Competition within the Market-place ....61

Competitor Ratio Analysis ....61

Clinical Trial Results ..61

TASQ .... 62

Mode of Action 62

Current Status .62

Proof of Concept ...62

Development Risks 62

Company Expertise 63

Competition within the Market-place ....63

Competitor Ratio Analysis ....63

Forecast ...63

VADIMEZAN 64

Mode of Action 64

Current Status .65

Proof of Concept/Clinical Data .65

Development Risks 65

Company Expertise 65

Competition Within the Market-place ...66

Competitor Ratio Analysis ....66

Forecast ...66

Source: Espicom. ..67

Clinical Trial Results ..67

PHASE III ... 69

ABIRATERONE ACETATE . 69

Mode of Action 69

Current Status .69

Proof of Concept ...69

Development Risks 70

Company Expertise 70

Competition within the Market-place ....70

Competitor Ratio Analysis ....71

Forecast ....71

AFLIBERCEPT .. 72

Mode of Action 72

Current Status .72

Proof of Concept/Clinical Data .72

Development Risks 73

Company Expertise 73

Competition within the Market-place ....74

Competitor Ratio Analysis ....75

Forecast ...75

Clinical Trial Results ..77

DASATINIB .. 79

Mode of Action 79

Current Status .79

Proof of Concept/Clinical Data .80

Development Risks 80

Company Expertise 81

Competition within the Market-place ....81

Competitor Ratio Analysis ....82

Forecast ...82

Clinical Trial Results ..83

DUTASTERIDE .. 85

Mode of Action 85

Sales ...85

Current Status .85

Proof of Concept ...86

Development Risks 86

Company Expertise 86

Competition within the Market-place ....86

Competitor Ratio Analysis ....87

Forecast ....87

Clinical Trial Results ....87

GVAX .... 88

Clinical Trial Results ....88

Monotherapy ...88

Combination with Ipilimumab ...89

IPILIMUMAB 90

Mode of Action 90

Current Status .91

Proof of Concept/Clinical Data .91

Development Risks 92

Company Expertise 92

Competition within the Market-place ....93

Competitor Ratio Analysis ....93

Forecast ...94

Clinical Trial Results ..95

MDV3100 ..... 98

Mode of Action 98

Current Status .98

Proof of Concept ...98

Development Risks 98

Company Expertise 99

Competition within the Market-place ....99

Competitor Ratio Analysis ....99

Forecast .100

PICOPLATIN ... 101

Mode of Action ....101

Current Status .....101

Proof of Concept/Clinical Data .....101

Development Risks ....102

Company Expertise ....102

Competition within the Market-place ..103

Patent Expiry .103

Competitor Ratio Analysis ..104

RADIUM-223 .... 105

Mode of Action ....105

Current Status .....105

Clinical Trial Results ..105

SUNITINIB MALATE ... 107

Mode of Action ....107

Current Status .....108

Proof of Concept/Clinical Data .....108

Development Risks ....109

Company Expertise ....110

Competition within the Market-place ..110

Data Exclusivity ...111

Patent Expiry .111

Generic Competition ..112

Competitor Ratio Analysis ..112

Forecast .112

Clinical Trial Results 115

TOREMIFENE .. 117

Mode of Action ....117

Current Status .....117

Proof of Concept/Clinical Data .....117

Development Risks ....118

Company Expertise ....118

Competition within the Market-place ..119

Competitor Ratio Analysis ..119

TRABECTEDIN 120

Mode of Action ....120

Current Status .....120

Further Development .120

Clinical Trial Results ..121

ZD4054 124

Mode of Action ....124

Current Status .....124

Proof of Concept .124

Development Risks ....124

Company Expertise ....124

Competition within the Market-place ..125

Competitor Ratio Analysis ..125

Forecast .126

Clinical Trial Results 127

FILED .. 128

CABAZITAXEL 128

Mode of Action ....128

Current Status .....128

Proof of Concept .128

Development Risks ....128

Company Expertise ....129

Competition within the Market-place ..129

Competitor Ratio Analysis ..129

Forecast ..129

Clinical Trial Results 130

SATRAPLATIN 132

Mode of Action ....132

Current Status .....132

Proof of Concept .132

Development Risks ....132

Company Expertise ....132

Competitor Ratio Analysis133

Forecast .133

APPROVED 134

BICALUTAMIDE .... 134

Mode of Action ....134

Current Status .....134

Proof of Concept .135

Development Risks ....136

Company Expertise ....137

Competition within the Market-place ..137

Generic Competition ..138

Competitor Ratio Analysis ..138

Forecast .139

CYPROTERONE ACETATE .... 140

Mode of Action ....140

Current Status .....140

DOCETAXEL ... 141

Mode of Action ....141

Sales .141

Current Status .....141

Proof of Concept .144

Development Risks ....149

Company Expertise ....150

Competition within the Market-place ..150

Competitor Ratio Analysis ..151

Forecast .152

Clinical Trial Results ..153

GOSERELIN .... 155

Mode of Action ....155

Current Status .....155

Proof of Concept/Clinical Data .....157

Development Risks ....158

Company Expertise ....158

Competition Within the Market-place .159

Patent Expiry .159

Generic Competition ..159

Competitor Ratio Analysis ..160

Forecast .160

LEUPRORELIN 163

Mode of Action ....163

Current Status .....164

Proof of Concept/Clinical Data .....165

Development Risks ....165

Company Expertise ....166

Competition within the Market-place ..166

Patent Expiry .167

Generic Competition ..167

Competitor Ratio Analysis ..167

Forecast ..168

MITOXANTRONE .. 169

Mode of Action ....169

Current Status .....169

Proof of Concept/Clinical Data .....169

Development Risks ....170

Company Expertise ....170

Competition within the Market-place ..170

Patent Expiry .170

Generic Competition ..170

Clinical Trial Results 171

SIPULEUCEL-T ..... 172

Mode of Action ....172

Current Status .....173

Proof of Concept/Clinical Data .....174

Development Risks ....175

Company Expertise ....175

Competition Within the Market-place .176

Competitor Ratio Analysis ..176

Forecast .176

Clinical Trial Results 177

WITHDRAWN .. 179

BEVACIZUMAB ..... 179

Mode of Action ....179

Current Status .....180

Proof of Concept/Clinical Data .....183

Development Risks ....186

Company Expertise ....187

Competition within the Market-place ..187

Competitor Ratio Analysis189

Forecast ..189

Clinical Trial Results ..194

SARACATINIB 198

Mode of Action ....198

METHODOLOGY ... 199

To order this report:Biotechnology Industry: Prostate Cancer Drug Futures

Biotechnology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved


Related medicine technology :

1. Reportlinker Adds Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors
2. Reportlinker Adds Deep Analysis Report on Chinas Disinfectant Market 2010-2015
3. Reportlinker Adds Renal Cell Carcimona Cancer Drug Futures
4. Reportlinker Adds The Top 10 CMOs in India: Market Dynamics, Competitive Positioning and Trends
5. Reportlinker Adds Global Minimally Invasive Surgery Market.(2010 - 2015)
6. Reportlinker Adds Global Diagnostic ECG Market (2010 - 2015)
7. Reportlinker Adds Global Wound Care Products Industry
8. Reportlinker Adds Global Veterinary Vaccines Industry
9. Reportlinker Adds Global Urological Catheters Industry
10. Reportlinker Adds Colorectal Cancer - France Drug Forecasts and Treatment Analysis to 2020
11. Reportlinker Adds Colorectal Cancer - Brazil, China, India and Russia (BRIC) Drug Drug Forecasts and Treatment Analysis to 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dublin ... of the " Global Markets for Spectroscopy Equipment" ... This report focuses on the global ... including its applications in various applications. The report deals ... three main industries: pharmaceutical and biotechnology, food and beverage, ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
Breaking Medicine Technology:
(Date:6/27/2016)... California (PRWEB) , ... June 27, 2016 , ... "FCPX ... fully customizable inside of Final Cut Pro X," said Christina Austin - CEO of ... unique style. Final Cut Pro X users can now reveal the media ...
(Date:6/27/2016)... Park, KS (PRWEB) , ... June 27, 2016 , ... ... in retailers of Eyeglasses . , Millions of individuals in the United States ... eyeglasses have become a way to both correct vision and make a fashion statement. ...
(Date:6/26/2016)... North Carolina (PRWEB) , ... June 26, 2016 , ... ... release of a new product that was developed to enhance the health of felines. ... for centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
Breaking Medicine News(10 mins):